Treatment of bullous pemphigoid with avdoralimab (IPH5401), an anti-C5aR1 monoclonal antibody - PB

CHU NICE0 个研究点目标入组 40 人开始时间: 2020年6月22日最近更新: 2020年9月28日

试验速览

暂无简介。

•Male or female
•= 18 years of age at the time of signing the informed consent document
•Clinical diagnosis of BP confirmed by histology, immunohistochemistry and/or ELISA data
•Patient requiring a treatment by superpotent topical steroids
•Patients hospitalized for the treatment of their BP
•For female, only post-menopaused patients
•For male patients included in the study with partners of child bearing potential should agree to use highly effective contraception for the duration of the study and 6 months after the last dose of avdoralimab
•Signed informed consent document prior to any study related assessments/procedures being conducted
•Patient able to adhere to the study visit schedule and other protocol requirements
•Patient registered to the French Social Security
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 30
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•Patients requiring systemic steroids according to the physician in charge
•Contra indication to topical steroid
•Use of systemic steroids or any immunosuppressive drugs in the past 4 weeks
•Use of doxycycline or minocycline in the past 4 weeks
•Use of systemic rituximab or omalizumab or dupilimumab in the past 12 weeks
•Use of intravenous immunoglobulmins (IVIG) in the past 4 weeks
•Impossibility to come every week to receive the injection
•Participants in other clinical therapeutic studies involving a drug that could interfere with the present evaluation
•Vulnerable people: pregnant or breast-feeding women, minors, adult under guardianship or deprived of freedom

发起方